It looks likely we'll see oral GLP-1 drugs on the market by next year, with pharmaceutical company Eli Lilly reporting impressive results following a large, robust 72-week trial that saw obese participants lose an average of 27.3 lb, or 12.4% of their body weight with the once-daily pill.| New Atlas
The latest scientific research and clinical treatment advances around obesity and weight loss.| New Atlas
Byproducts from gut bacteria breaking down tryptophan, a dietary amino acid, can restore hormone-secreting gut cells reduced by obesity, a new study found. It opens the door to a natural, side-effect-free alternative to GLP-1 drugs like Ozempic.| New Atlas
The latest scientific research and clinical treatment advances for chronic pain| New Atlas
The latest scientific research and clinical treatment advances around Alzheimer's disease and dementia.| New Atlas
